- Home
- ACP vs STTK Comparison
ACP vs STTK Comparison
Compare ACP & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | STTK |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 637.4M | 652.4M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACP | STTK |
|---|---|---|
| Price | $4.33 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | ★ 994.1K | 931.7K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.12 | $1.72 |
| 52 Week High | $5.76 | $8.33 |
Technical Indicators
Market Signals| Indicator | ACP | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 40.68 |
| Support Level | $4.12 | $3.55 |
| Resistance Level | $4.49 | $5.98 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 71.61 | 35.03 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.